

PRIMARY Plan of Care

REGENERATIVE THERAPY

PRODUCTS

ImunStem and Aktiffvate

COMPANY

Golden Sunrise Nutraceutical, Inc.
219 N. "E" Street
PORTERVILLE, CA 93257 * U.S.A.
Phone No.: 1.559.781.0658
Fax No.: 1.559.615.1268



TABLE OF CONTENTS

<u>SECTION</u>	<u>PAGE NUMBER</u>
Title Page	Cover Page
Table of Contents	1
1.0 Indication and Usage	2
2.0 Treatment, Dosage and Administration	2
2.1 Administration of ImunStem and Aktiffvate	2
2.2 Ongoing Treatment	2
3.0 Warning and Precautions	2
4.0 Drug Interactions	3
5.0 Therapeutic Response	3
5.1 Adverse Sensitivity Response of ImunStem and Aktiffvate	3
6.0 Clinical Pharmacology	3
6.1 Mechanism of Action	3
6.2 Pharmacokinetics	4
7.0 Nonclinical Toxicology	4
7.1 Genotoxicity of ImunStem	4
7.2 Genotoxicity of Aktiffvate	4
8.0 Results of Patients After Treatment	5
9.0 Dietary Supplement Labels	10
9.1 ImunStem and Aktiffvate	10
10.0 How Supplied/Packaging	10
10.1 Packaging	10
Primary Plan of Care – END	11



1.0 INDICATIONS AND USAGE

This guidance is designed as the first use **PRIMARY Plan of Care** for all conditions or diseases and is used to stabilize the patient. *ImunStem* and *Aktiffvate* stimulates the immune system throughout the body. *ImunStem* and *Aktiffvate* aids the cellular regeneration of damaged areas of the body through diseases and injuries. *ImunStem* and *Aktiffvate* also helps blood flow through the system especially in difficult regions such as body capillaries. *ImunStem* and *Aktiffvate* are a highly mobile compound that has been shown as a central nervous system and immune system stimulant.

2.0 TREATMENT, DOSAGE AND ADMINISTRATION

Take ½ – ¾ of a dropper of *ImunStem* and *Aktiffvate* under tongue 1–4 times daily. Leave under the tongue for approximately 40–seconds and the drink water.

If the patient has a sensitivity of the mouth and/or throat then an administration orally mixed with 1–teaspoonful of yogurt or capsules can be administered.

2.1 Administration and Dosage of IMUNSTEM and AKTIFFVATE

Upon the first visit it is suggested that once a medical evaluation of the patient is completed and that the medical staff deems it appropriate, then patients will receive ½ – ¾ of a dropperful of *ImunStem* and *Aktiffvate* 1–4 times a day. The medical staff should monitor the patient for at least 10–minutes to help with any effects that might need medical attention. For example, *ImunStem* can open and improve blood flow throughout the body and the patient might experience a feeling of warmth and begin having nasal discharge of mucus. After 10–minutes if the patient is stable, the ¾–dropper of *Aktiffvate* should be administered with similar monitoring.

ImunStem and *Aktiffvate* are liquid form:

Product	Dosage Per day	Dose Size of dropper
<i>ImunStem</i>	1–4	½ - ¾
<i>Aktiffvate</i>	1–4	½ - ¾

2.2 Ongoing Treatment

The patient should receive ½ – ¾ of a dropperful of *ImunStem* and *Aktiffvate* between 1–4 times daily for the first 2–weeks. Then another medical evaluation should be performed to evaluate their effectiveness and to determine if reduction in dose to 2–3 times daily is appropriate. Blood test before treatment, and at 2–4 weeks can be helpful to evaluate effectiveness. If the patient appears to be stable, then other Golden Sunrise Nutraceutical product supplementation should be added to specific conditions or diseases of the patient. All future treatments should take into account any physicians evaluations, blood reports or other information pertinent to the treatment of the patient.

3.0 WARNING AND PRECAUTIONS

ADMINISTRATION OF **IMUNSTEM** AND **AKTIFFVATE** SHOULD ALWAYS BE UNDER THE SUPERVISION OF A PHYSICIAN. RECOMMENDATION FOR GOLDEN SUNRISE

NUTRACEUTICAL **PRIMARY OF CARE** IS BASED ON MEDICAL EVALUATION OF THE SUPERVISION OF A PHYSICIAN.

4.0 DRUG INTERACTIONS

ImunStem and *Aktiffvate* has been combined with other drugs, but has not been thoroughly tested with significant combinations yet to show interactions with multiple combinations. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or dietary supplements, you should speak with a qualified healthcare provider before starting a new therapy.

5.0 THERAPEUTIC RESPONSE

5.1 Adverse Sensitivity Response of *ImunStem* and *Aktiffvate*

- In rare circumstances an adverse reaction in the mouth such as mild blisters have occurred.
- A burning sensation in the throat in the beginning of oral treatment may then usually occur but subsides. If the burning sensation persists, capsules may be substituted as an alternative.
- Vomiting.
- *ImunStem* and *Aktiffvate* can cause severe allergic skin rashes.

6.0 CLINICAL PHARMACOLOGY

6.1 Mechanism of Action

ImunStem and *Aktiffvate* are herbal (botanical) products which help to regenerate the cell and promote the cellular metabolism to return to homeostasis in the human body.

It is postulated that in arresting abnormal cellular mutation, the precursors for normal and enhanced cellular regeneration and cellular division can be accelerated in relation to the selective existing disease pathology. It is therefore theorized that the combination of the body's thermal energy, particularly during variance mutation and inflammatory processes, potentiates the self-propelling of molecules by possible passive membrane transportation or passive diffusion of the *ImunStem* and *Aktiffvate* intact across all cell membranes, including the blood-brain barrier, which allows its efficacy for the central nervous system.

ImunStem and *Aktiffvate* possess a bipolarity and a lipophilicity that facilitates molecular diffusion through various permeable and selective membranes. In-vivo studies on test subjects have indicated that the cell membrane integrity remains intact and is not disrupted or destroyed in the process of assimilating into the cell, thus ensuring long-term effectiveness.

ImunStem and *Aktiffvate* are the key for the effectiveness of the products on the immune system and cellular metabolism. They have immune-stimulating properties. In-vivo studies on treated patients demonstrate increasing phagocytic activity and synthesis of helper cell function. *ImunStem* and *Aktiffvate* have shown to transform Deoxyribonucleic Acid / Ribonucleic Acid (DNA / RNA) repair, before, during and after chemotherapy drugs,

prescription drugs, toxic exposure and chemical induced damage. The variety of these herbals have many effects including antioxidant activity and anti-inflammatory properties.

ImunStem and *Aktiffvate* can play an integral role in hypothalamic activity, easing both parasympathetic and sympathetic nervous systems towards a state of homeostasis. For example, blood pressure level is directly linked to the sympathetic nervous system and the low blood pressure levels exhibited following administration of *ImunStem* and *Aktiffvate* are compatible with the stabilization of the sympathetic nervous system activity. *ImunStem* and *Aktiffvate* inflammation by affecting immune responsiveness through neuroendocrine factors. Improvement of balance problems, a side-effect of some chemotherapies, by Golden Sunrise Nutraceutical products is thought to be from improvement of vestibular function.

6.2 Pharmacokinetics

ImunStem and *Aktiffvate* are readily adsorbed into soft tissue when taken as an oral dose. This is accomplished because *ImunStem* and *Aktiffvate* readily passes through membrane tissue by passive diffusion.

The *ImunStem* and *Aktiffvate* dietary supplements are metabolized by the body to more hydrophilic products that are excreted by the kidneys in the urine and by the gastrointestinal tract in the feces.

7.0 NONCLINICAL TOXICOLOGY

7.1 Genotoxicity of *ImunStem*

PURPOSE: The purpose of this study is to evaluate *ImunStem* for its ability to induce reverse mutation at the histidine locus in *Salmonella typhimurium* tester strains both in the presence and absence of an exogenous mammalian metabolic system (S9) containing microsomal enzyme.

CONCLUSION: Under the test conditions in this study, *ImunStem* was not mutagenic in the tested strains of the *Salmonella typhimurium*, histidine auxotroph TA97, TA98, TA100, TA102 and TA1535 both in the presence and absence of metabolic activation system. The results indicated that, at the dose concentration of a 25-fold dilution to a 15,625-fold dilution of original liquid, 100- μ l/plate, *ImunStem* did not induce point mutations by base substitutions and/or frame shifts in the genome of these tested strains.

7.2 Genotoxicity of *Aktiffvate*

PURPOSE: The *Salmonella typhimurium* reverse mutation assay (Ames test) is used to determine the potential mutagenic activity of the test article by exposing a large number of the test organism to the test article in agar plates. The agar plates are monitored for growth of revertants (organism mutating to the wild type) which are counted and used to estimate the mutagenic potential of the test article.

The Ames test employs several histidine dependent (His-) strains of *Salmonella typhimurium* which require the amino acid histidine for growth. The test detects mutations which cause the bacterial strains to revert to histidine independent (His+) bacteria which are capable of synthesizing histidine and can grow in the absence of histidine. The assay uses tester strains TA97a, TA98, TA100, TA102 and TA1535 which were selected to detect various types of mutagens. The test is performed both with and without metabolic activation using an S-9 activation system. The S-9 activation system is designed to simulate mammalian liver enzyme systems and is used to detect substances which undergo metabolic activation from non-mutagenic forms.

All test method acceptance criteria were met. The test procedure(s) listed above were followed without deviation.

CONCLUSION: The results are calculated using a validated computer program. Manual calculations may differ slightly due to rounding. All results greater than three hundred (300) Colony Forming Units (CFU) are considered estimates.

Doses 5- μ l/plate and 1.6- μ l/plate showed toxicity; therefore, two (2) additional lower concentrations were tested to complete the dose range. The test article concentrations did not produce a 2-fold or 3-fold increase in the number of revertants or produce a clear dose related response in any of the five (5) tester strains. The spot tests of dose 5- μ l/plate showed no zone of increased reversion, but did show toxicity. In PURPOSE, the test article concentrations tested against the 5-strains did not meet the criteria for a potential mutagen.

8.0 **RESULTS OF PATIENTS AFTER TREATMENT**

A small group of patients with *Serious or Life-threatening* diseases or conditions found that *ImunStem* and *Aktiffvate* dietary supplement improved the immune system and alertness immediately.

Physicians have observed that using *ImunStem* and *Aktiffvate* provokes a significant response, i.e., a reduction in symptoms in patients with these diseases: Autism, Alzheimer's, Neuropathy, Chronic Lymphocytic Leukemia, Multiple Sclerosis, Parkinson's, Schizoaffective disorder, Fragile-X syndrome, and a significant decrease of side-effects to chemotherapy for cancer. *ImunStem* and *Aktiffvate* has been shown to help reduced loss of blood from surgical wound and menstrual periods (shorter and lighter periods).

Fifty 50-patients administered *ImunStem* and *Aktiffvate* dietary supplement over the course of time from a few weeks up to 3-years were made and included observations from attending physicians, nursing staff, care givers and Golden Sunrise Nutraceutical medical personnel. Blood reports were also included and medications (if any) were documented. The observations compiled from family physicians and specialists were entered and compared with observations by Golden Sunrise Nutraceutical medical staff.

Safety was monitored and throughout these studies no adverse side-effects were noticed. A representative number of patients were diagnosed with *Serious or Life-threatening* diseases or

conditions that required close monitoring by both the attending physician, specialist of that field and by Golden Sunrise Nutraceutical medical staff.

- a) J.W. is a 10-years-old white male who began treatment with physician psychiatrist in VISALIA California when he 6-year-old. He has been diagnosed with fragile-X syndrome. He was diagnosed as Attention Deficit Hyperactivity Disorder (ADHD) (F90.1), and Intermittent Explosive Disorder (IED) (F63.81). He has been treated over the years with Tegretol, Vyvanse, Zoloft, Risperdal; he had a trial at another medical center of R Baclofen. Psychiatrist have also treated him with Gabitril, and Nudexta. He was taking Zoloft 150-mg in the morning, Risperdal 1-mg at bedtime and Vyvanse 40-mg in the morning.

In July 07, 2016 he was started *ImunStem* and *Aktiffvate* 20-drops twice a day was started at that point in time. On July 25, 2016 his mother reports as of this date that he is more focused and calmer. His level of perseveration has decreased dramatically. His mother stated that the other day he was organizing the DVDs player in their home and "that's not like him."

- b) S.W. is a 64-years-old, white male, who began treatment with psychiatrist when he was 57-year-old. He was initially diagnosed as anxiety disorder Not Otherwise Specified (NOS) (F41.9) and ADHD without hyperactivity (F90.0). Stimulant medication was not effective in treating his focusing problems so Wellbutrin was used. Chlorazepate was used to help with his anxiety. He did well on this combination of medicines until November 2014. He was diagnosed at that point in time as having diabetic neuropathy and was treated with Lyrica. He complained at that point in time that the medicine made him feel "fuzzy" and he was unable to be productive at work. In February 2015 he stopped the Chlorazepate because he was afraid of having Alzheimer's disease and decreased the Wellbutrin on his own to decrease the fuzziness. He did restart the Chlorazepate eventually. In April 2016 he was taking Cymbalta 60-mg in the morning and Ambien 10-mg at bedtime. His family doctor had stopped the Wellbutrin and Chlorazepate. He was being treated at that point in time with methadone and Lyrica. He complained again of feeling fuzzy, tired, and unable to do his work.

In July 2016 he was started with *ImunStem* and *Aktiffvate* 20-drops twice a day. He reported 2½ weeks later that he had more energy and motivation. He was more productive and able to do his work and his pain had been reduced by thirty (30%) percent.

- c) S.R. is a 39-years-old white male, who was first seen when he was 28-year-old. He was transferred from another physician and was taking Wellbutrin-SR 100-mg 3-times a day, Clozaril 600-mg at bedtime, Zoloft 200-mg in the morning, Topamax 100-mg at bedtime, and Aricept 20-mg at bedtime. He had a significant history of substance abuse, including marijuana, crack cocaine, mushrooms, and acid between the ages of seventeen and 17-year-old and 21-year-old. He was diagnosed as schizoaffective disorder (F25.9) and Polysubstance abuse. He was treated with multiple medications over the years to try to help reduce his psychotic symptoms and increased his sociability. In June 2016, he was taking Vraylar 6-mg in the morning, Fanapt 6-mg twice a day, Nudexta 20-10 twice a day, Chlorazepate 30-mg at bedtime, Prozac 40-mg in the morning, Clozaril 300-mg at bedtime, Abilify 30-mg in the morning, and Gabitril 4-mg at bedtime.

In July 07, 2016 he was started with *ImunStem* and *Aktiffvate* 20-drops twice a day were started at that point in time. He returned on July 21, 2016, reporting that he had decreased the Chlorazepate to 15-mg at bedtime, his Prozac had been increased to 60-mg in the morning and he had been on *ImunStem* and *Aktiffvate* for 2-weeks as well as the other medications listed above. He reported "my brain can keep up with my mind". He stated "my brain is aware of my body". He reported increased energy, clearer thoughts, and non-racing thoughts. He also reported that he had a dry patch of skin on the back of his head that was now gone.

- d) L.H. is an 86-years-old, white female, who is diagnosed as having Alzheimer's disease and lives in a skilled nursing facility. She is on a liquid diet, sleeps most of the time, is confined to a wheelchair or a moving bed, and has intermittent episodes of agitation and flat facies. She was treated with *ImunStem* and *Aktiffvate* 10-drops twice a day for 2-1/2-weeks. Both staff and family report that she is less agitated, more alert and is smiling.

After 30-days on *ImunStem* and *Aktiffvate* the nurses' report there are no longer any agitated episodes. Skilled nursing report that she spends more time awake. On exam, the patient opened her eyes and focused on my face. There was no facial expression, but patient appeared to try and move her lips as if she wanted to talk. (This was a new behavior). When I asked her to move her finger if she could understand me, she did.

- e) M.B. is a 69-years-old white male who has been treated for chronic Lymphocytic Leukemia for the last 5-years. He started taking *ImunStem* and *Aktiffvate* 20-drops twice a day in October 2015. This was because of the concern of falling Red Blood Cell (RBC) counts and platelet counts. His White Blood Cell (WBC) count, though elevated remained elevated and fluctuant. In October 2015, his RBC was 4.05-count and his platelet was 90-count. On April 2016 his RBC was 4.19-count and his platelet was 105-count. It was felt that this was a significant increase in both his RBC count and platelet count. Please see table below as following:

Comparison RBC Count and Platelet Count from October, 2015 through April, 2016

DATE	RBC Count	Platelet Count	
October, 2015	4.05	90	Before <i>ImunStem</i>
April, 2016	4.19	105	After <i>ImunStem</i>

- f) R.B. is a 62-years-old white male who was first evaluated on August 19, 2016. He is taking Actos, Metformin, Lorstan, and Travastin for diabetes mellitus, high blood pressure, and glaucoma. There is no history of past substance abuse. He was interested in trying *ImunStem* and *Aktiffvate* to see if would make any difference with his medical problems. He also complains of mild symptoms of depression including anergia, lack of motivation and feeling depressed about his physical problems. He was diagnosed as depressive disorder NOS and started on *ImunStem* and *Aktiffvate* 20-drops twice a day.

Patient reported after 8-weeks of *ImunStem* and *Aktiffvate* treatment that his energy and motivation have been increased. He also reported that he was feeling less depressed. He

reported that he was able to tolerate higher loads of carbohydrates without changing his diabetes medications, which also affect directly his energy and motivation.

- g) J.O. is a 45-years-old white male diagnosed with advanced stage-4 colon cancer. He was diagnosed in January 2016 and was not thought by the attending physician that he could have a positive outcome as the cancer was in mastitis and had spread throughout his body. His symptoms included a damaged liver, renal obstruction, lung polyps, anxiety, depression, and severe lack of energy. The patient received first cycle of chemotherapy on March 2016.

In April 2016 the patient received his first dose of *ImunStem* and *Aktiffvate* administered orally at 40-drops three times daily. At this time the patient showed noticeable improvement of overall health in minutes. The patient showed an improvement in energy levels as the next day he was playing basketball, mental focus, depression and anxiety improved noticeably and his outlook on life is a positive hope. His tumors have shrunk and since the treatments of *ImunStem* and *Aktiffvate* chemotherapy he has had no major side-effects such as hair loss, debilitating constipation, depression, anxiety, weight loss, or nausea. He has not had to visit emergency for complications except for a staph infection at his injection port. Patient is doing well and can function without interference to his normal lifestyle. The patient has been motivated to tell others of the benefits of taking *ImunStem* and *Aktiffvate* that it can help others in *Serious or Life-threatening* conditions.

- h) J.A. is a 2½-years-old male that was diagnosed with Autism/Seizure. His symptoms included, seizure, drooling, hyperactivity, disorientation, lack of pain stimuli, poor communication skills and uncontrollable outbursts. He was diagnosed in October 2016 and was considered near the highest level of Autism that provided government programs to assist with his mental state. He has an unknown regimen of prescription medications and government assistance is provided for re-education of motor skills.

In December 2016 he began oral administration of *ImunStem* and *Aktiffvate* at 2-drops per 12-fl.oz. of milk. In about 4-days was noticed by the parents that he was aware of his surroundings and responded to the parents' direction. He was also noticed to stop drooling and felt pain in normal situations (such as falling down while playing). He also began to have a reduction in seizures. He has improved where there are no known seizures being observed at this time and he is more responsive to direction, his drooling has not returned and he is beginning to act as a normal 2½-years-old.

- i) S.R. is a 62-years-old black male that was diagnosed with advanced stage Parkinson's disease. He was diagnosed 4-years-ago and has had a steady progression of the Parkinson's disease. The symptoms include, slurred speech, an unsteady (uneven) gait, memory loss, depression, tremors and occasional falling. He has taken the prescribed medication which had only intermittent results.

In April 2015 he began taking *ImunStem* and *Aktiffvate* oral administration at 30-drops twice a day. He states that he feels more stable as he can walk on his own, has no more falling

episodes, can focus better (clearer thought), has reduced tremors and has significantly reduced his depression. He has also returned to his previous employment.

- j) R.W. is a 16-years-old female that has excessive menstrual bleeding and long painful menstrual periods since 2013. She took Vicodin every month on the first day of her period. She had debilitating pain that interfered with her lifestyle and activities and kept her confined to her home.

In October 2016 she began taking *ImunStem* and *Aktiffvate* oral administration at 30-drops per day. After 3-weeks her menstrual bleeding reduced greatly and her pain had been alleviated. Her period duration had dropped by half and she is able to function in public as a normal.

- k) R.G. is a 60-years-old male diagnosed with an enlarged prostate. He had been to multiple medical professionals that have treated him for everything from bleeding eye to heart attack. Physicians have recommended various surgeries for his prostate but the patient did not want to have these surgeries because of the possible adverse outcomes.

In October 2017 he was administered *ImunStem* and *Aktiffvate* while in the hospital being treated, within 3-minutes he felt an improved feeling to his prostate which felt like less pressure and less pain. He continued to improve over 4-months and no longer requires invasive procedures to alleviate prostate swelling. Please see table below as following:

Comparison eGFR, WBC and Platelet Count from October, 2017 through December, 2017

DATE	eGFR	WBC Count	Platelet Count	
October, 2017	15	6.36	136	Before <i>ImunStem</i>
December, 2017	40	8.00	332	After <i>ImunStem</i>

- l) E.B. is a 46-years-old white male was diagnosed with Multiple Sclerosis (MS) in November 2016. He was first suspect as having lime disease but upon further testing it was found to be MS. He experienced a continual degradation of motor function until he was bedridden, he had almost total immobility of his legs and arms. The caregiver would assist the patient for all movement including bathroom activities.

Patient began taking *ImunStem* and *Aktiffvate* in October 2017 and showed positive response for the first dose. Over the course of treatments the patient has experienced improved motor function to where he can sit in a wheelchair and move himself and can sit on the toilet without the aid of the caregiver. The patient continues to show marked improvement as the treatment progresses. The see table below as following:

Comparison WBC and Platelet Count from September, 2017 through December, 2017

DATE	WBC Count	Platelet Count	
September, 2017	6.04	206	Before <i>ImunStem</i>
December, 2017	9.60	254	After <i>ImunStem</i>

m) R.H. is a 54-years-old white male was diagnosed in December 26, 2016 with esophageal cancer in stage-2 after the patient collapsed for no apparent reason and began spewing blood. The patient was rushed to the local emergency room where testing immediately began and the diagnosis was made. The patient refused standard medical cancer treatment (chemotherapies).

The patient began taking *ImunStem* and *Aktiffvate* in February 20, 2017, and shown improvements in both reports the blood reports and medical scans. The physician at the hospital after reviewing the blood report and medical scans his recommendation “resume regular diet” and to receive another checkup in 4-weeks. Please see table below as following:

Comparison WBC, Mean Platelet Volume and Platelet from January, 2017 through March, 2017

DATE	WBC	Mean Platelet Volume	Platelet	
January, 2017	6.40	6.90	375	Before <i>ImunStem</i>
March, 2017	9.40	8.40	332	After <i>ImunStem</i>

9.0 DIETARY SUPPLEMENT LABELS

9.1 ImunStem and Aktiffvate

10.0 HOW SIPLIED/PACKAGING

10.1 Packaging

PRODUCT	CONTAINER CONTENT	NET CONTENT
ImunStem	1-bottle	1-fl.oz. Liquid
Aktiffvate	1-bottle	1-fl.oz. Liquid

PRIMARY Plan of Care

January, 2019

END



10.0 ATTACHMENT

10.1 ImunStem and Aktiffvate



ImunStem®

Dietary Supplement

WARNING

Keep out of reach of children
do not use if safety seal is damaged or missing

SUPPLEMENT FACTS		
Serving Size: (0.50ml) (491.50mg)		
Serving Per Container: 59 serving		
Amount Per Serving		%DV
Olive Leaf extract	260mg	**
Yarrow extract	52mg	**
Rosemary extract	63mg	**
** Daily Value (DV) not established.		

Other Ingredients: Organic compounds and solvents, monoterpene, fatty acid, cassia oil and yucca.

STRUCTURE FUNCTION

“Support Immunity” and “Boost Stamina”

“For the Relief of Occasional Sleeplessness”

“Maintains Healthy Lung Function”

“Helps Restore Mental Alertness or Wakefulness when Experiencing Fatigue or Drowsiness”

“Helps You Relax”

ADVERSE ACTIONS

- * In rare circumstances an adverse reaction in the mouth such as “mild blisters” have occurred.
- * A burning sensation in the throat in the beginning of oral treatment may then usually occur but subsides. If the burning sensation persists, capsules may be substituted as an alternative.
- * Vomiting.
- * Yarrow flowers can cause severe allergic skin rashes.

Administration: Shake bottle well before using and use dropper to place $\frac{1}{2}$ – $\frac{3}{4}$ of *ImunStem* under tongue. Leave under tongue for approximately 40-seconds and then swallow with a drink of water.

Dosage: Take $\frac{1}{2}$ – $\frac{3}{4}$ dropperful, 1–4 times a day, as frequently as every 1–3 hours.

ImunStem dietary supplement may support immunity, improve overall health for the human body and maintain good well-being.

WARNING: Not recommended for use by pregnant or nursing women. Should you have any questions regarding the use of *ImunStem*, please consult your doctor or call the product hot line in U.S. at 1.559.781.0658 or 1.559.361.0097. Keep out of reach of children. To be kept in a dry and cool place.

* These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure or prevent any disease.

Aktiffvate®

Dietary Supplement

WARNING

Keep out of reach of children
do not use if safety seal is damaged or missing

SUPPLEMENT FACTS		
Serving Size: (0.50ml) (491.50mg)		
Serving Per Container: 25 serving		
Amount Per Serving		%DV
Turmeric extract	175mg	**
Cayenne extract	40mg	**
Eucalyptus extract	20mg	**
** Daily Value (DV) not established.		

Other Ingredients: Wintergreen, solvents, organic compounds, fatty acids, Yucca and Olive leaf.

STRUCTURE FUNCTION

“Support Immunity” and “Boost Stamina”

“For the Relief of Occasional Sleeplessness”

“Maintains Healthy Lung Function”

“Helps Restore Mental Alertness or Wakefulness when Experiencing Fatigue or Drowsiness”

“Helps You Relax”

“Helps Maintain Cardiovascular Function and a Healthy Circulatory System”

“Reduces Stress and Frustration”

ADVERSE ACTIONS

* In rare circumstances an adverse reaction in the mouth such as “mild blisters” have occurred.

* A burning sensation in the throat in the beginning of oral treatment may then usually occur but subsides. If the burning sensation persists, capsules may be substituted as an alternative.

* Vomiting.

Administration: Shake bottle well before using and use dropper to place ½ – ¾ dropperful of *Aktiffvate* under tongue. Leave under tongue for approximately 40-seconds and then swallow with a drink of water.

Dosage: Take ½ – ¾ quarter of a dropper, 1–4 times a day, as frequently as every 1–3 hours.

Aktiffvate dietary supplement may support immunity, improve overall health for the human body and maintain good well-being.

WARNING: Not recommended for use by pregnant or nursing women. Should you have any questions regarding the use of *Aktiffvate*, please consult your doctor or call the product hot line in U.S. at 1.559.781.0658 or 1.559.361.0097. Keep out of reach of children. To be kept in a dry and cool place.

* These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure or prevent any disease.



Manufactured by: **Golden Sunrise Nutraceutical, Inc.**
P.O. Box 510
PORTERVILLE, CA 93257 * U.S.A.

Aktiffvate is a Registered Trademark of Golden Sunrise Pharmaceutical, Inc.